Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accounts Payables (2020 - 2026)

InMed Pharmaceuticals has reported Accounts Payables over the past 5 years, most recently at $1.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 86.55% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 86.55%, while the annual FY2025 figure was $1.4 million, 124.26% up from the prior year.
  • Accounts Payables for Q4 2025 was $1.1 million at InMed Pharmaceuticals, up from $369088.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $2.1 million in Q2 2021 and troughed at $369088.0 in Q3 2025.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2022 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: plummeted 69.59% in 2023 and later skyrocketed 166.31% in 2024.
  • Year by year, Accounts Payables stood at $2.1 million in 2021, then plummeted by 44.96% to $1.1 million in 2022, then rose by 12.41% to $1.3 million in 2023, then crashed by 55.38% to $574563.0 in 2024, then skyrocketed by 86.55% to $1.1 million in 2025.
  • Business Quant data shows Accounts Payables for INM at $1.1 million in Q4 2025, $369088.0 in Q3 2025, and $1.4 million in Q2 2025.